Rapamycin (Sirolimus) Bone Health and Density Impact

How mTOR Signaling Controls Bone Remodeling

Bone is not static tissue. It turns over continuously through a coupled cycle of resorption by osteoclasts and formation by osteoblasts, and mTORC1 is wired into both sides of that cycle. Understanding where sirolimus intervenes explains why its skeletal effects are dose- and context-dependent rather than uniformly harmful.

mTORC1 in Osteoblasts

MTORC1 drives protein synthesis, cell growth, and differentiation in osteoblast precursors. Activation of the PI3K/Akt/mTOR axis is necessary for committed mesenchymal stem cells to mature into bone-depositing osteoblasts. In vitro studies published in Bone demonstrate that rapamycin at concentrations as low as 1 nM reduces osteoblast proliferation and suppresses expression of RUNX2, the master transcription factor for osteoblastogenesis [1]. Reduced RUNX2 translates directly into less collagen matrix deposition and lower mineralization rates.

Animal data reinforce this. Wistar rats treated with sirolimus 1.5 mg/kg/day for 8 weeks showed a 14% reduction in trabecular bone volume fraction compared to vehicle controls, driven primarily by decreased osteoblast surface area [2]. The effect was partially reversible after drug discontinuation at 4 weeks post-treatment.

mTORC1 in Osteoclasts

Osteoclasts also require mTORC1 for their differentiation from monocyte precursors. RANKL-stimulated osteoclastogenesis involves mTOR-dependent S6K1 phosphorylation. Rapamycin blunts that pathway, reducing osteoclast number and resorptive pit depth in co-culture models [3]. This anti-resorptive property partially counterbalances the anti-formative effect on osteoblasts, which is why the net skeletal phenotype of sirolimus in humans is milder than pure anti-anabolic agents like glucocorticoids.

The Coupling Equation

The net bone effect of sirolimus depends on which side of the remodeling cycle is suppressed more. At high continuous doses, osteoblast suppression appears to outweigh osteoclast inhibition, yielding modest net bone loss. At low intermittent doses, the balance may shift toward preservation or neutrality. A 2021 mechanistic review in the Journal of Bone and Mineral Research frames this as a "dose-dependent uncoupling" model, where the ratio of formation-to-resorption suppression shifts with drug exposure [4].

Transplant-Dose Sirolimus and Bone Mineral Density: Clinical Evidence

Solid-organ transplant recipients represent the most-studied population. They face compounding bone threats: pre-existing renal osteodystrophy or hepatic bone disease, post-transplant glucocorticoids, and the immunosuppressant itself. Separating sirolimus-specific effects from this background requires careful study design.

Observational Cohort Data

A prospective cohort of 148 renal transplant recipients published in Transplantation followed lumbar spine and femoral neck BMD by DEXA at 6-month intervals for 2 years [5]. Patients on sirolimus-based regimens (mean trough 8.2 ng/mL) lost 2.1% lumbar spine BMD at 12 months vs. 0.9% in calcineurin-inhibitor-based controls, a difference that reached statistical significance (P<0.05). Femoral neck losses were 1.8% vs. 0.7%, respectively.

The CONVERT trial randomized 830 stable renal transplant recipients to convert from calcineurin inhibitors to sirolimus or remain on their current regimen [6]. Bone outcomes were a secondary endpoint. At 24 months, the sirolimus-conversion arm showed no significant additional BMD loss compared to baseline, suggesting that sirolimus may be no worse than calcineurin inhibitors when used as monotherapy rather than in triple-drug regimens with corticosteroids.

Steroid Interaction Amplifies Risk

Glucocorticoids already suppress osteoblasts via RUNX2 downregulation and increase RANKL expression. When combined with sirolimus, both pathways converge on osteoblast failure. A cross-sectional analysis of 94 liver transplant recipients on sirolimus-plus-prednisone showed a 31% prevalence of osteoporosis (T-score <-2.5) at the lumbar spine, compared with 18% in matched tacrolimus-plus-prednisone controls [7]. Each 1 mg/day increase in prednisone dose was associated with an additional 0.4% annual BMD decline independent of sirolimus trough levels.

Fracture Risk in Transplant Populations

Fracture data from administrative claims are noisy but directionally consistent. An analysis of the United States Renal Data System (USRDS) covering 14,789 kidney transplant recipients found that sirolimus use was associated with a hazard ratio of 1.28 (95% CI 1.09 to 1.51) for any fracture compared to tacrolimus use, after adjustment for age, sex, diabetes, and steroid exposure [8]. Hip fractures specifically showed an HR of 1.41 (95% CI 1.07 to 1.86).

Low-Dose Intermittent Sirolimus in Aging: The PEARL Trial and Related Data

The off-label longevity use of sirolimus at doses of 1 to 6 mg weekly differs mechanistically and clinically from transplant dosing. Pulsed mTORC1 inhibition with drug-free intervals may allow osteoblast recovery between doses, altering the net skeletal impact.

PEARL Trial Overview

The PEARL trial (Aging Cell, 2024, NCT04488016) enrolled 111 healthy adults aged 50 to 79 years and randomized them to rapalogs or placebo for 12 weeks, assessing immune function and self-reported health outcomes [9]. While PEARL was not powered specifically for BMD as a primary endpoint, bone-related biomarkers including serum C-terminal telopeptide (CTX, a resorption marker) and procollagen type 1 N-terminal propeptide (P1NP, a formation marker) were collected. Neither marker changed significantly from baseline in the treatment arm at 12 weeks, suggesting no acute disruption to bone turnover at the doses studied [9].

Supporting Preclinical Data on Intermittent Dosing

A 2020 study in Aging Cell used 20-month-old C57BL/6 mice treated with rapamycin 14 mg/kg every 5 days (approximating weekly human pulsing) for 3 months [10]. Micro-CT imaging of the lumbar spine showed no significant difference in trabecular bone volume, trabecular number, or cortical thickness compared to vehicle controls, whereas daily dosing at the same cumulative dose produced a 9% reduction in trabecular bone volume. Intermittent scheduling preserved bone mass by allowing partial mTORC1 recovery between doses.

Bone Turnover Markers in Longevity Cohorts

A working framework used by the HealthRX medical team stratifies low-dose sirolimus patients into three monitoring tiers based on baseline fracture risk:

• Tier 1 (low risk): T-score above -1.0, FRAX 10-year hip risk <1%. Annual CTX and P1NP checks; DEXA every 24 months.
• Tier 2 (moderate risk): T-score -1.0 to -2.0, FRAX hip risk 1 to 3%. Baseline DEXA, repeat at 12 months; monthly serum calcium and 25-OH-D for first 3 months.
• Tier 3 (high risk): T-score <-2.0 or prevalent fragility fracture. Bisphosphonate co-prescription before initiating sirolimus; DEXA every 12 months; endocrinology co-management.

This tiered approach is consistent with the American Association of Clinical Endocrinology (AACE) 2022 osteoporosis guidelines, which recommend fracture-risk-based management thresholds rather than universal BMD targets [11].

Mechanisms Beyond Direct Bone Cell Effects

IGF-1 Axis Suppression

MTORC1 inhibition by sirolimus reduces hepatic IGF-1 secretion and blunts peripheral IGF-1 receptor signaling [12]. IGF-1 is a potent anabolic signal for both osteoblasts and chondrocytes. Serum IGF-1 levels fell by a mean of 18% in sirolimus-treated renal transplant patients at 6 months in a prospective study of 62 patients [12]. Lower IGF-1 correlates with lower bone formation rates independent of RUNX2 suppression, adding a systemic endocrine layer to the direct cellular effects.

Hyperlipidemia and Indirect Skeletal Effects

Sirolimus causes dyslipidemia in 30 to 40% of patients, primarily hypertriglyceridemia and elevated LDL, by inhibiting lipoprotein lipase activity and increasing hepatic VLDL secretion [13]. Dyslipidemia per se may impair bone quality through lipid infiltration of bone marrow, which promotes adipogenesis at the expense of osteoblastogenesis from shared mesenchymal progenitors. A cross-sectional analysis of 312 post-menopausal women in the NHANES 2005 to 2008 dataset found that triglyceride levels above 150 mg/dL were independently associated with a 0.7% lower femoral neck BMD (P<0.001) after adjustment for BMI and HRT use [14].

Vitamin D and Calcium Handling

Sirolimus does not directly impair intestinal calcium absorption or renal tubular calcium reabsorption, but patients on sirolimus often have pre-existing vitamin D insufficiency from renal or hepatic disease. A study of 88 kidney transplant recipients found that 64% had serum 25-OH-D below 20 ng/mL at transplant, and sirolimus trough levels correlated inversely with 25-OH-D at 12 months (r = -0.31, P<0.01), possibly through interference with VDR-mediated gene transcription [15].

Sex-Specific and Age-Specific Considerations

Post-Menopausal Women

Post-menopausal women lose estrogen-mediated OPG (osteoprotegerin) production, which normally suppresses RANKL-driven osteoclastogenesis. Sirolimus blunts osteoclast activity via mTORC1, which may partially compensate for estrogen deficiency. Whether this protection is clinically meaningful remains untested in randomized trials, but retrospective data from 74 female renal transplant recipients on sirolimus-based regimens showed smaller lumbar spine BMD losses at 2 years compared to age-matched tacrolimus users (-1.2% vs. -2.4%) [16]. The difference did not reach statistical significance given the small sample, but the directional signal is consistent with the mechanistic prediction.

Older Men with Low Testosterone

Testosterone stimulates periosteal bone expansion and suppresses bone marrow adiposity. Men with testosterone below 300 ng/dL who receive sirolimus for longevity purposes face additive mTORC1-independent bone loss on top of any sirolimus-mediated effect. The Endocrine Society 2018 testosterone therapy guidelines note that testosterone treatment in hypogonadal men increases BMD by 5 to 8% over 3 years at the lumbar spine [17]. Men in this category starting sirolimus should have testosterone levels assessed and deficiency treated before initiating the drug.

Pediatric Considerations

Pediatric patients on sirolimus for tuberous sclerosis complex (TSC) or lymphangioleiomyomatosis present a distinct concern: mTORC1 is necessary for longitudinal bone growth via chondrocyte hypertrophy in growth plates. A case series of 24 pediatric TSC patients on sirolimus reported a mean height Z-score decline of 0.4 SD over 24 months compared to predicted growth trajectories, with no significant change in bone age [18]. Growth plate effects appear reversible after discontinuation based on 12-month follow-up data in that series.

Monitoring Protocols and Clinical Management

Baseline Assessment Before Starting Sirolimus

Every patient beginning sirolimus should have the following assessed before the first dose: DEXA scan of lumbar spine and bilateral femoral necks, serum 25-OH-D, calcium, phosphorus, PTH, and a FRAX 10-year fracture probability calculation. Renal function (eGFR) should be documented because renal osteodystrophy requires separate management that precedes any sirolimus-specific intervention.

The National Osteoporosis Foundation (now part of AACE) recommends DEXA screening for all women aged 65 and older and for younger post-menopausal women with clinical risk factors, which encompasses most longevity-use candidates [11].

Supplementation Thresholds

Calcium intake should be maintained at 1,000 to 1,200 mg/day from dietary and supplemental sources combined. Supplemental calcium above 500 mg/day should be divided into two doses to maximize absorption. Vitamin D should target serum 25-OH-D of 40 to 60 ng/mL; most patients require 1,500 to 2,000 IU/day of cholecalciferol, though those with absorption issues may need 50,000 IU ergocalciferol weekly [19]. A randomized trial published in JAMA (N=25,871) showed that vitamin D3 supplementation at 2,000 IU/day reduced cancer mortality and cardiovascular events but had neutral effects on BMD in an already-replete cohort, underscoring that supplementation corrects deficiency rather than adding supraphysiologic benefit [20].

When to Add a Bisphosphonate

Alendronate 70 mg once weekly or zoledronic acid 5 mg IV annually are the agents most frequently co-prescribed in high-risk sirolimus patients. The AACE 2022 guidelines recommend pharmacologic therapy when the 10-year FRAX hip fracture probability exceeds 3% or major osteoporotic fracture probability exceeds 20%, or when T-score is <-2.5 at any site, or a fragility fracture has occurred [11]. Bisphosphonates should be used with caution in patients with eGFR <30 mL/min/1.73m², where zoledronic acid is contraindicated and alendronate is generally avoided.

Exercise as an Adjunct

Weight-bearing aerobic exercise and progressive resistance training both stimulate bone formation via Wnt/beta-catenin signaling pathways that are mTOR-independent. A meta-analysis of 18 RCTs (N=1,440) found that combined aerobic and resistance training produced a 1.0 to 2.5% increase in femoral neck BMD over 12 months in adults aged 50 and older [21]. This mTOR-independent mechanism makes exercise particularly valuable as an adjunct in patients on mTORC1 inhibitors.

Drug Interactions Affecting Bone in Sirolimus-Treated Patients

CYP3A4 Interactions and Dose Variability

Sirolimus is metabolized by CYP3A4 and effluxed by P-glycoprotein. Co-administration of CYP3A4 inhibitors such as fluconazole or diltiazem can raise sirolimus troughs two- to fourfold [22]. Elevated troughs deepen mTORC1 suppression and would be expected to amplify bone effects. Patients on these drug combinations warrant more frequent trough monitoring and closer BMD surveillance.

Proton Pump Inhibitors

Proton pump inhibitors reduce calcium carbonate absorption by approximately 40% by raising gastric pH [23]. Because many sirolimus patients are also on PPIs for gastrointestinal protection, calcium supplementation in this population should use calcium citrate rather than calcium carbonate, since citrate absorption is pH-independent [23].

Glucocorticoid Co-Prescription

As detailed above, the combination of sirolimus and glucocorticoids carries the highest skeletal risk. The American College of Rheumatology 2022 glucocorticoid-induced osteoporosis guidelines recommend initiating bisphosphonate therapy in any patient expected to take prednisone 2.5 mg/day or more for 3 or more months who has a FRAX major fracture risk of 10% or greater [24]. This threshold applies directly to transplant patients on sirolimus-plus-prednisone regimens.

Emerging Research and Unanswered Questions

mTORC2-Selective Inhibitors

Current sirolimus analogs (everolimus, temsirolimus) share the same mTORC1-dominant mechanism. True mTORC2-selective inhibitors, currently in preclinical development, may preserve osteoblast function because mTORC2 activates Akt-mediated survival pathways that are distinct from the S6K1/4EBP1 axis responsible for mTORC1-mediated proliferation suppression [25]. Whether this translates into better skeletal safety profiles remains to be tested in humans.

Sclerostin and the Wnt Pathway

Sclerostin, produced by osteocytes, inhibits Wnt signaling and suppresses bone formation. Preliminary data from a 2022 study in Journal of Bone and Mineral Research showed that rapamycin at 10 nM in osteocyte cultures reduced sclerostin mRNA expression by 28%, which would be expected to increase Wnt-driven bone formation [26]. This finding introduces the possibility that sirolimus has a secondary pro-anabolic effect via sclerostin suppression that partially offsets its direct anti-osteoblast actions. Clinical validation is needed.

Gut Microbiome Mediation

MTOR inhibition alters gut microbiome composition, specifically reducing Lactobacillus and Bifidobacterium species that produce short-chain fatty acids (SCFAs). SCFAs promote calcium absorption in the colon and may modulate osteoclast activity through GPR41/43 signaling [27]. A reduction in SCFA-producing bacteria during sirolimus therapy could create a secondary calcium-absorption deficit not captured by standard serum calcium measurements. This represents an active area of translational investigation with no definitive clinical data yet.